Table 4.
Hematologic tests performed during the oral administration period.
| Test items | Clinical laboratory reference values | Group | Week 0 | Week 2 | Week 4 | Week 6 (observation period) |
|---|---|---|---|---|---|---|
| Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | Mean ± S.D. | |||
| White blood cell count (× 103/μL) | Female: 3.6–9.0 | Placebo | 5.8 ± 0.8 | 5.9 ± 1.0 | 5.5 ± 0.8 | 5.7 ± 1.1 |
| Male: 3.9–9.8 | NMN | 5.9 ± 1.7 | 5.1 ± 1.3 | 5.3 ± 1.5 | 5.8 ± 1.8 | |
| Red blood cell count (× 104/μL) | Female: 370–500 | Placebo | 473.1 ± 38.0 | 478.0 ± 34.9 | 464.9 ± 37.2 | 456.3 ± 39.3 |
| Male: 430–570 | NMN | 489.8 ± 40.3 | 487.4 ± 43.4 | 479.6 ± 43.3 | 466.8 ± 39.9 | |
| Hemoglobin (g/dL) | Female: 11.3–15.2 | Placebo | 14.8 ± 1.3 | 15.0 ± 1.3 | 14.7 ± 1.5 | 14.4 ± 1.5 |
| Male: 13.5–17.6 | NMN | 14.9 ± 1.2 | 14.9 ± 1.4 | 14.8 ± 1.5 | 14.5 ± 1.2 | |
| Hematocrit (%) | Female: 34–45 | Placebo | 44.5 ± 3.7 | 44.8 ± 3.7 | 43.6 ± 3.9 | 42.6 ± 3.8 |
| Male: 40–52 | NMN | 44.9 ± 3.7 | 44.8 ± 4.0 | 44.0 ± 4.1 | 42.7 ± 3.5 | |
| Platelet count (× 104/μL) | Female: 13.0–36.9 | Placebo | 25.3 ± 5.2 | 25.1 ± 5.0 | 24.1 ± 5.5 | 24.2 ± 5.7 |
| Male: 13.1–36.2 | NMN | 26.5 ± 3.4 | 27.2 ± 4.1 | 25.6 ± 4.4 | 26.2 ± 3.8 | |
| MCV (fl) | Female: 79–100 | Placebo | 94.0 ± 4.3 | 93.7 ± 3.9 | 93.8 ± 3.8 | 93.3 ± 3.6 |
| Male: 83–102 | NMN | 91.9 ± 4.8 | 91.9 ± 4.4 | 91.8 ± 4.8 | 91.7 ± 4.6 | |
| MCH (pg) | Female: 26.3–34.3 | Placebo | 31.3 ± 1.5 | 31.4 ± 1.6 | 31.6 ± 1.6 | 31.6 ± 1.8 |
| Male: 28.0–34.6 | NMN | 30.5 ± 1.8 | 30.6 ± 1.8 | 30.9 ± 1.9 | 31.1 ± 2.0 | |
| MCHC (%) | Female: 30.7–36.6 | Placebo | 33.3 ± 0.5 | 33.5 ± 0.5 | 33.7 ± 0.7 | 33.8 ± 0.9 |
| Male: 31.6–36.6 | NMN | 33.2 ± 0.8 | 33.2 ± 0.8 | 33.6 ± 1.1 | 33.9 ± 1.1 | |
| HbA1c (NGSP) (%) | 4.6–6.2 | Placebo | 5.3 ± 0.2 | 5.2 ± 0.2 | 5.3 ± 0.2 | 5.2 ± 0.3 |
| NMN | 5.3 ± 0.2 | 5.2 ± 0.2 | 5.3 ± 0.2 | 5.2 ± 0.2 |
MCV mean corpuscular volume, MCH mean corpuscular hemoglobin concentration, MCHC mean corpuscular hemoglobin concentration, NGSP national glycohemoglobin standardization program.
The number of participants in the placebo group was n = 15, while the NMN group comprised n = 16. Statistical significance was determined by two-way analysis of variance and Dunnett's post hoc-test (two-tailed test) was used to compare the initial value measured at week 0 with all subsequent measurements. Between-group differences comparisons were made using a paired t-test or Welch’s t-test (only white blood cell count).